Bupropion induced hypertensive crisis in a healthy male with no prior hypertension
DOI:
https://doi.org/10.59736/IJP.23.03.969Keywords:
Bupropion, Caffeine , Hypertension, Hypertensive Crisis, Norepinephrine Dopamine Reuptake InhibitorAbstract
Background: Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) indicated in treatment of depression, attention deficit hyperactivity disorder (ADHD) and for smoking cessation. Although hypertension is a known side effect, hypertensive crises in previously normotensive individuals is rarely reported.
Case Report: A 26-year-old male took bupropion for depressive symptoms during his exams, but his condition worsened after he started consuming excessive amounts of caffeine and energy drinks. The combination of bupropion and excessive caffeine intake led to hypertension and tachycardia. During his first visit to the emergency department, he presented with a blood pressure of 160/90 mmHg and a heart rate of 110 bpm. On a subsequent visit, these values had increased to 180/110 mmHg and 132 bpm, respectively. Workup ruled out other secondary causes. The symptoms resolved after discontinuation of bupropion.
Conclusion: Clinicians should monitor blood pressure in all patients, including those without known cardiovascular risk.
References
Clark A, Tate B, Urban B, Schroeder R, Gennuso S, Ahmadzadeh S, et al. Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation. Health Psychol Res. 2023; 11:81043. Doi: 10.52965/001c.81043.
Huecker MR, Smiley A, Saadabadi A. Bupropion. [Updated 2024 Sep 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470212/.
Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2020; 4(4):CD000031. Doi: 10.1002/14651858.CD000031.pub5.
Han J, Kim M, Kim Y, Lee SH, Shin S, Choi YJ. Identifying Predictors of Serious Adverse Events in Antidepressant Treatment from a Decade-Long Nationwide Pharmacovigilance Study: Impact of Dementia and Parkinson's disease Treatment. Medicina (Kaunas). 2025; 61(6):1103. Doi: 10.3390/medicina61061103.
Harini K, Alomar SY, Vajagathali M, Manoharadas S, Thirumalai A, Girigoswami K, et al. Niosomal Bupropion: Exploring Therapeutic Frontiers through Behavioral Profiling. Pharmaceuticals (Basel). 2024; 17(3):366. Doi: 10.3390/ph17030366.
Waris B, Butt NI, Afzal A, Ghoauri MSA, Khizar I, Mahmood K, et al. Exploring knowledge of hypertension and treatment adherence in hypertensive patients from Lahore, Pakistan. Cureus. 2025; 17(4):e81762. Doi: 10.7759/cureus.81762.
Calvi A, Fischetti I, Verzicco I, Belvederi-Murri M, Zanetidou S, Volpi R, et al. Antidepressant Drugs Effects on Blood Pressure. Front Cardiovasc Med. 2021; 8:704281. Doi: 10.3389/fcvm.2021.704281.
Aronow WS. Drug-induced causes of secondary hypertension. Ann Transl Med. 2017; 5(17):349. Doi: 10.21037/atm.2017.06.16.
Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23):3095-105. Doi: 10.1001/jama.289.23.3095.
Kandukuru A, Sharma P, Verghese-Gupta S, Nkembo A, Sutariya V. Cardiovascular adverse events associated with norepinephrine-dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System. Can J Physiol Pharmacol. 2024; 102(12):709-719. Doi: 10.1139/cjpp-2024-0128.
Ahmed H, Ismayl M, Palicherla A, Selim M, Aboeata A. Bupropion-disguised chest pain presenting in a middle-aged male: a case report and review of literature. Ann Med Surg (Lond). 2024; 86(7):4213-4216. Doi: 10.1097/MS9.0000000000002175
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Nadia Siddiq, Usama Abbas, Noor Fatima Rauf, Barak Waris, Nauman Ismat Butt
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
